Difference between revisions of "Cervical cancer - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%" to "{| class="wikitable sortable" style="width: 100%") |
|||
| Line 42: | Line 42: | ||
# '''GOG 141:''' Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the Gynecologic Oncology Group. Gynecol Oncol. 2007 Aug;106(2):362-9. Epub 2007 May 9. [https://www.gynecologiconcology-online.net/article/S0090-8258(07)00264-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/17493669 PubMed] | # '''GOG 141:''' Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the Gynecologic Oncology Group. Gynecol Oncol. 2007 Aug;106(2):362-9. Epub 2007 May 9. [https://www.gynecologiconcology-online.net/article/S0090-8258(07)00264-8/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/17493669 PubMed] | ||
# '''JCOG 0102:''' Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, Yasugi T, Yaegashi N, Yokota H, Kodama S, Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T; [[Study_Groups#JCOG|JCOG]]. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013 May 28;108(10):1957-63. Epub 2013 May 2. [https://www.nature.com/articles/bjc2013179 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671094/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23640393 PubMed] NCT00190528 | # '''JCOG 0102:''' Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, Yasugi T, Yaegashi N, Yokota H, Kodama S, Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T; [[Study_Groups#JCOG|JCOG]]. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013 May 28;108(10):1957-63. Epub 2013 May 2. [https://www.nature.com/articles/bjc2013179 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671094/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23640393 PubMed] NCT00190528 | ||
| + | |||
| + | =Adjuvant therapy= | ||
| + | ==Observation== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | ===Regimen=== | ||
| + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 20%"|Study | ||
| + | !style="width: 20%"|Years of enrollment | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 20%"|Comparator | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |Awaiting publication (OUTBACK) | ||
| + | |2011-2017 | ||
| + | | style="background-color:#1a9851" |Phase III (C) | ||
| + | |Carboplatin & Paclitaxel | ||
| + | | style="background-color:#ffffbf" |Did not meet primary endpoint of OS | ||
| + | |- | ||
| + | |} | ||
| + | ''No further treatment after definitive therapy.'' | ||
| + | ====Preceding treatment==== | ||
| + | *Cisplatin-based chemoradiation | ||
| + | ===References=== | ||
| + | *'''OUTBACK:''' ACTRN12610000732088 | ||
[[Category:Cervical cancer regimens]] | [[Category:Cervical cancer regimens]] | ||
Revision as of 16:08, 4 June 2021
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main cervical cancer page for current regimens.
Neoadjuvant therapy
No neoadjuvant therapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Herod et al. 2000 | 1986-1995 | Phase III (C) | BIP | Did not meet primary endpoints of ORR/OS |
| Eddy et al. 2007 (GOG 141) | 1996-2001 | Phase III (C) | Cisplatin & Vincristine | Did not meet primary endpoints of PFS/OS |
| Katsumata et al. 2013 (JCOG 0102) | 2001-2005 | Phase III (C) | BOMP | Did not meet primary endpoint of OS |
No systemic therapy prior to surgery.
Subsequent treatment
References
- Herod J, Burton A, Buxton J, Tobias J, Luesley D, Jordan S, Dunn J, Poole CJ. A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. Ann Oncol. 2000 Sep;11(9):1175-81. link to original article PubMed
- GOG 141: Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E, O'Connor D. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the Gynecologic Oncology Group. Gynecol Oncol. 2007 Aug;106(2):362-9. Epub 2007 May 9. link to original article PubMed
- JCOG 0102: Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, Yasugi T, Yaegashi N, Yokota H, Kodama S, Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T; JCOG. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013 May 28;108(10):1957-63. Epub 2013 May 2. link to original article link to PMC article PubMed NCT00190528
Adjuvant therapy
Observation
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Awaiting publication (OUTBACK) | 2011-2017 | Phase III (C) | Carboplatin & Paclitaxel | Did not meet primary endpoint of OS |
No further treatment after definitive therapy.
Preceding treatment
- Cisplatin-based chemoradiation
References
- OUTBACK: ACTRN12610000732088